Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 75-79

  Kim, Joo Hyun ^a   Ryu, Seunghyong ^a   Nam, Hee Jung ^b   Lim, Meerae ^c   Baek, Ji Hyun ^a   Joo, Yeon Ho ^d   Kwon, Jun Soo ^e   Ha, Tae Hyon ^c   Hong, Kyung Sue ^a,f  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul Metropolitan Eunpyeong Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Samsung Medical Center   (South Korea)

Author keywords

Explanatory factor analysis; Obsessive compulsive symptoms; Schizophrenia; Second generation antipsychotics; Symptom dimension

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLEANING; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; OBSESSIVE HOARDING; PATIENT IDENTIFICATION; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYMPTOM ASSESSMENT;

EID: 84864517348     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.011     Document Type: Article

References (32)

1. Alevizos B., Papageorgiou C., Christodoulou G.N. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 2004, 7:375-377.
2. Baer L. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 1994, 55(Suppl.):18-23.
3. Baker R.W., Chengappa K.N., Baird J.W., Steingard S., Christ M.A., Schooler N.R. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992, 53:439-442.
4. Bloch M.H., Landeros-Weisenberger A., Rosario M.C., Pittenger C., Leckman J.F. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008, 165:1532-1542.
5. Cavallini M.C., Di Bella D., Siliprandi F., Malchiodi F., Bellodi L. Exploratory factor analysis of obsessive-compulsive patients and association with 5-HTTLPR polymorphism. Am J Med Genet 2002, 114:347-353.
6. de Haan L., Linszen D.H., Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 1999, 60:364-365.
7. Diler R.S., Yolga A., Avci A., Scahill L. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol 2003, 13(Suppl. 1):S89-S92.
8. Ertugrul A., Anil Yagcioglu A.E., Eni N., Yazici K.M. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 2005, 59:219-222.
9. Faragian S., Pashinian A., Fuchs C., Poyurovsky M. Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1009-1012.
10. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
11. Ha T.H., Youn T., Rho K.S., Kim M.S., Kwon J.S. Symptom dimensions of obsessive-compulsive disorder and their relation to comorbid personality pathology. J Korean Neuropsychiatr Assoc 2004, 43:46-53.
12. Hahn O.S., Ahn J.H., Song S.H., Cho M.J., Kim J.K., Bae J.N., et al. Development of Korean version of structured clinical interview schedule for DSM-IV axis I disorder: interrater reliability. J Korean Neuropsychiatr Assoc 2000, 39:362-372.
13. Hasler G., LaSalle-Ricci V.H., Ronquillo J.G., Crawley S.A., Cochran L.W., Kazuba D., et al. Obsessive-compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. Psychiatry Res 2005, 135:121-132.
14. Hasler G., Kazuba D., Murphy D.L. Factor analysis of obsessive-compulsive disorder YBOCS-SC symptoms and association with 5-HTTLPR SERT polymorphism. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:403-408.
15. Hasler G., Pinto A., Greenberg B.D., Samuels J., Fyer A.J., Pauls D., et al. Familiality of factor analysis-derived YBOCS dimensions in OCD-affected sibling pairs from the OCD collaborative genetics study. Biol Psychiatry 2007, 61:617-625.
16. Hwang M.Y., Kim S.W., Yum S.Y., Opler L.A. Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am 2009, 32:835-851.
17. Ke C.L., Yen C.F., Chen C.C., Yang S.J., Chung W., Yang M.J. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci 2004, 20:295-301.
18. Kim S.J., Choi N.K., Hong H.J., Hwang Y.S., Kim Y.K., Lee H.S., et al. Dimensional analyses of the Yale-Brown obsessive-compulsive scale and Yale-Brown obsessive-compulsive scale checklist. Korean J Psychopharmacol 2004, 15:339-345.
19. Kwon J.S., Joo Y.H., Nam H.J., Lim M., Cho E.Y., Jung M.H., et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 2009, 66:1233-1241.
20. Leckman J.F., Grice D.E., Boardman J., Zhang H., Vitale A., Bondi C., et al. Symptoms of obsessive-compulsive disorder. Am J Psychiatry 1997, 154:911-917.
21. Lim M., Park D.Y., Kwon J.S., Joo Y.H., Hong K.S. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 2007, 27:712-713.
22. Lykouras L., Alevizos B., Michalopoulou P., Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:333-346.
23. Mahendran R., Liew E., Subramaniam M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry 2007, 68:542-545.
24. Mataix-Cols D., Rauch S.L., Manzo P.A., Jenike M.A., Baer L. Use of factor-analyzed symptom of dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999, 156:1409-1416.
25. Mataix-Cols D., Marks I.M., Greist J.H., Kobak K.A., Baer L. Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosom 2002, 71:255-262.
26. Mataix-Cols D., Rauch S.L., Baer L., Eisen J.L., Shera D.M., Goodman W.K., et al. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry 2002, 159:263-268.
27. Ozer S., Arsava M., Ertugrul A., Demir B. Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:724-727.
28. Pinto A., Greenberg B.D., Grados M.A., Bienvenu O.J., Samuels J.F., Murphy D.L. Further development of YBOCS dimensions in the OCD collaborative genetics study: symptoms vs. categories. Psychiatry Res 2008, 160:83-93.
29. Poyurovsky M., Weizman A., Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004, 18:989-1010.
30. Rufer M., Grothusen A., Mass R., Peter H., Hand I. Temporal stability of symptom dimensions in adult patients with obsessive-compulsive disorder. J Affect Disord 2005, 88:99-102.
31. Ryu S., Oh S., Cho E.Y., Nam H.J., Yoo J.H., Park T., et al. Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:949-959.
32. Stamouli S., Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006, 26:396-400.